JOYN Advisors’s Rein Therapeutics RNTX Stock Holding History

JOYN Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$10K	Hold	1,500	–	–	﹤0.01%	107
2019 Q4	$17K	Hold	1,500	–	–	﹤0.01%	125
2019 Q3	$20K	Hold	1,500	–	–	﹤0.01%	118
2019 Q2	$16K	Hold	1,500	–	–	﹤0.01%	126
2019 Q1	$59K	Hold	1,500	–	–	0.01%	115
2018 Q4	$25K	Hold	1,500	–	–	0.01%	587
2018 Q3	$83K	Buy	+1,500	New	+$101K	0.02%	263

Other funds holding RNTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

GPFA

Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return

IWAG

Integer Wealth Advisors Group Cartersville, Georgia $184M AUM 62.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

JOYN Advisors's RNTX Position: Q1 2020 in Review

JOYN Advisors held its Rein Therapeutics (RNTX) position steady in Q1 2020 at 1,500 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #107.

JOYN Advisors first reported a position in RNTX in Q3 2018 and has held it in 7 quarters since. The position peaked at $83K in Q3 2018. 20 funds tracked by Wall St. Rank hold RNTX as of Q1 2020.

JOYN Advisors held 1,500 shares of Rein Therapeutics worth $10K as of Q1 2020.
JOYN Advisors left its Rein Therapeutics share count unchanged in Q1 2020.
Rein Therapeutics made up ﹤0.01% of JOYN Advisors's portfolio in Q1 2020, its #107 holding.
JOYN Advisors first reported a position in Rein Therapeutics in Q3 2018 and has held it in 7 quarters since.
JOYN Advisors's Rein Therapeutics position peaked at $83K in Q3 2018.
20 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2020.

Based on JOYN Advisors's 13F filing for Q1 2020, filed 30 Apr 2020.